Cardiogenic shock can occur due to acute ischaemic or non-ischaemic cardiac events, or
from progression of long-standing underlying heart disease. When addressing the cause of …

The use of temporary mechanical circulatory support in cardiogenic shock has increased
dramatically despite a lack of randomized controlled trials or evidence guiding clinical …

Cardiogenic shock is associated with significant morbidity and mortality, and clinicians have
increasingly used short-term mechanical circulatory support (MCS) over the last 15 years to …

Objectives: To review temporary percutaneous mechanical circulatory support devices for
the treatment of cardiogenic shock, including current evidence, contraindications …

Cardiogenic shock (CS) is associated with hemodynamic compromise and end-organ
hypoperfusion due to a primary cardiac etiology. In addition to vasoactive medications …

Despite a high rate of early revascularization and use of intra-aortic balloon pump
counterpulsation therapy, the prognosis of patients with cardiogenic shock has remained …

Cardiogenic shock remains a challenging disease entity and is associated with significant
morbidity and mortality. Temporary mechanical circulatory support (MCS) can be …

Cardiogenic shock is the clinical expression of circulatory failure, as a consequence of left,
right or biventricular dysfunction. Cardiogenic shock is also defined as a state of critical end …

Background: Temporary mechanical circulatory support (MCS) devices provide
hemodynamic assistance for shock refractory to pharmacological treatment. Most registries …

The Shock Academic Research Consortium is a multi-stakeholder group, including
representatives from the US Food and Drug Administration and other government agencies …